This result correlates with the expression data obtained inFig. correlated with an increase in total cholesterol level and a decrease inSREBP-2expression and protein. Finally, we found that individuals with high cholesterol had a 5-fold increase in serum miR-185 expression compared with control individuals. Thus, miR-185 controls cholesterol homeostasis Ikarugamycin through regulating SREBP-2 expression and activity. In turn, SREBP-1c regulates miR-185 expression through a complex cholesterol-responsive feedback loop. Thus, a novel axis regulating cholesterol homeostasis exists that exploits miR-185-dependent regulation of SREBP-2 and requires SREBP-1c for function. Keywords:microRNA, Ikarugamycin metabolism, cholesterol, transcription, sterol response element binding protein Cholesterol is a key lipid of eukaryotic cell membranes and is an essential precursor for steroid hormone and bile acid syntheses. The dysregulation of cholesterol homeostasis is tightly associated with various metabolic diseases, including atherosclerosis and type 2 diabetes (1,2). Besides taking up cholesterol in the form of apolipoprotein B-containing lipoproteins, particularly LDL by the LDL receptor (LDLR), animal cells de novo synthesize cholesterol from acetyl-CoA through a series of enzymatic reactions (17). Genes coding for enzymes involved in the de novo pathway are subject to transcriptional regulation by the sterol response element binding protein (SREBP) family of Ikarugamycin transcription factors (8). SREBP family members are basic-helix-loop-helix leucine zipper transcription factors that bind to sterol response elements (SREs) and promote gene expression (9). SREBP-1a, SREBP-1c, and SREBP-2 comprise the family and are encoded by two distinct genes,SREBF-1andSREBF-2. SREBP-2 is the main regulator of de novo cholesterol biosynthesis, controlling the transcription of cholesterol biosynthetic genes, including HMG-CoA reductase (HMGCR) and squalene synthase (FDFT1), as well asLDLRandPCSK9(8). On the other hand SREBP-1c targets genes involved in fatty acid metabolism (10). Although SREBP-1a regulates fatty acid and cholesterol-related Ikarugamycin gene expression, SREBP-1c expression level predominates in the liver (11). Intracellular cholesterol concentration is tightly regulated by feedback mechanisms controlling the cleavage/activation and nuclear translocation of SREBPs. When the level of cholesterol is high, SREBP-2 is bound to a SCAP-insulin signaling gene (INSIG) complex in the endoplasmic reticulum (8), whereas when the level of cholesterol decreases, SCAP disassociates from INSIG and guides the translocation of SREBP-2 from the endoplasmic reticulum to the Golgi (8,12). There in the Golgi, full-length SREBP-2 is cleaved by site-1 protease/site-2 protease and converted to a soluble mature SREBP-2 transcription factor that translocates to the nucleus, where it binds SREs in the promoters of sterol-responsive genes (12,13). Elucidating the mechanisms controlling the expression and activation of SREBP-2 is key to our understanding of cholesterol metabolic regulation. The events regulating the transcriptional expression ofSREBP-2, and the posttranslational modifications affecting SREBP-2 activity are well documented (1426). On the other hand, microRNA (miR)-dependentSREBP-2posttranscriptional regulation is only now being explored. miRs are 22 nucleotide single-stranded small noncoding RNAs. miRs can suppress gene expression posttranscriptionally by imperfect pairing to microRNA response elements (MREs) within 3UTRs of target mRNAs. miR regulation results in the inhibition of target gene expression through mRNA degradation and/or translational inhibition (27,28). miRs are transcribed from locations throughout the genome within the introns and exons of protein-coding genes, as well as multiple intragenic regions. miRs can be transcriptionally regulated by changes in promoter activity (2934). The aberrant expressions of certain miRs are associated with cardiometabolic diseases (27,35,36). miR-185 and its role in cell biology first came to light when a connection was discovered between miR-185 expression and cancer progression. For instance, miR-185 overexpression suppressed the migration and invasiveness of LNCaP prostate cancer cells (37), while its repression led to cisplatin resistance in SKOV3/DDP ovarian cell lines (38). Moreover, specific miR-185 SNPs have an inverse relationship with breast cancer risk, suggesting this miR may have biomarker attributes (39). miR-185 targets include RhoA, Cdc42, DNA methyltransferase 1, the androgen receptor, and the Six1 oncogene (37,4042). While evidence is accumulating establishing the miR-185 cancer connection, its role in regulating lipid metabolism is obscure. Very recently, miR-185 was shown to repress selective HDL-cholesterol uptake through the inhibition of scavenger receptor BI (SR-BI) expression in human hepatic cells (43). This is the only report linking miR-185 to any type of lipid metabolic regulation. Interestingly, another miR, miR125a-5p, was also found to inhibit SR-BI expression in steroidogenic cells (44). We tested several miRs (miR-1260, -532, -324, and -185) potentially targeting the 3UTR ofSREBP-2for the ability to modulateSREBP-2expression. Of those tested, only miR-185 was found to significantly reduceSREBP-2expression. Rabbit polyclonal to PFKFB3 Here, studies show that miR-185 regulatesSREBP-2expression, which in turn regulatesLDLRexpression and LDL uptake. Moreover, evidence is presented for the first time showing that SREBP-1c regulates miR-185 expression, thus there is a feedback loop that precisely regulates miR-185 activity.